News, Short Squeeze, Breakout and More Instantly...
Mr. Claiborne Joined the CytRx Board of Directors as of the Annual Meeting CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, welcom...
KemPharm Sees Promise in Arimoclomol for Niemann-Pick Disease Type C, and Plans to Resubmit to FDA as Early as Q1 2023 CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and developmen...
Company Begins Planning First-in-Human Studies of Next-Generation LADR Drugs CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, toda...